Literature DB >> 23678983

Rocuronium and sugammadex in patients with myasthenia gravis undergoing thymectomy.

Z Sungur Ulke1, A Yavru, E Camci, B Ozkan, A Toker, M Senturk.   

Abstract

BACKGROUND: The use of neuromuscular blocking agents is still controversial in myasthenic patients but rocuronium could be useful after the introduction of sugammadex as a selective antagonist. The aim of the study was to evaluate the use of rocuronium-sugammadex in myasthenic patients undergoing thoracoscopic thymectomy.
METHODS: After ethical approval, 10 myasthenic patients undergoing videothoracoscopic-assisted thymectomy were enrolled in the study. Neuromuscular block was achieved with 0.3 mg/kg rocuronium and additional doses were given according to train-of-four (TOF) monitoring or movement of the diaphragm. Sugammadex 2 mg/kg was given after surgery. Recovery time (time to obtain a TOF value > 0.9) was recorded for all subjects. RESULT: All patients were extubated in the operating room after administration of sugammadex. Mean rocuronium dose was 48 mg and the average operation time was 62 min. Recovery time after sugammadex administration was 111 s (min 35; max 240).
CONCLUSIONS: A rapid recovery of neuromuscular function was found in myasthenic patients receiving rocuronium when sugammadex was used for reversal. This combination could be a rational alternative for myasthenic patients for whom neuromuscular blockade is mandatory during surgery.
© 2013 The Acta Anaesthesiologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23678983     DOI: 10.1111/aas.12123

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  10 in total

1.  New diagnosis myasthenia gravis and preeclampsia in late pregnancy.

Authors:  John Ozcan; Ian Frank Balson; Alicia T Dennis
Journal:  BMJ Case Rep       Date:  2015-02-26

2.  Sugammadex in the management of myasthenic patients undergoing surgery: beyond expectations.

Authors:  Michele Carron; Alessandro De Cassai; Federico Linassi
Journal:  Ann Transl Med       Date:  2019-12

3.  Anaesthetic management of myasthenia gravis in coronary artery bypass grafting.

Authors:  Vinayak Vanjari; Marc O Maybauer
Journal:  Ann Card Anaesth       Date:  2020 Apr-Jun

4.  Magnesium sulfate reduces the rocuronium dose needed for satisfactory double lumen tube placement conditions in patients with myasthenia gravis.

Authors:  Shoujun Fei; Hengfu Xia; Xiaowei Chen; Dazhi Pang; Xuebing Xu
Journal:  BMC Anesthesiol       Date:  2019-08-31       Impact factor: 2.217

5.  Myasthenia gravis and sugammadex: A case report and review of the literature.

Authors:  Sujana Dontukurthy; Carrie Wisler; Vidya Raman; Joseph D Tobias
Journal:  Saudi J Anaesth       Date:  2020-03-05

6.  Comparison of recovery profiles in patients with Parkinson's disease for 2 types of neuromuscular blockade reversal agent following deep brain stimulator implantation.

Authors:  Yong-Seok Park; Jaewon Kim; Sung-Hoon Kim; Young-Jin Moon; Hye-Mee Kwon; Hee-Sun Park; Wook-Jong Kim; Seungil Ha
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.817

7.  Incomplete recovery from rocuronium-induced muscle relaxation in patients with amyotrophic lateral sclerosis using sugammadex: A case report.

Authors:  Hea Rim Chun; Jinhun Chung; Nan Seol Kim; A Joo Kim; Suro Kim; Kyu Sik Kang
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

8.  Use of sugammadex in patients with neuromuscular disorders: a systematic review of case reports.

Authors:  Usha Gurunathan; Shakeel Meeran Kunju; Lisa May Lin Stanton
Journal:  BMC Anesthesiol       Date:  2019-11-19       Impact factor: 2.217

Review 9.  Advantages and pitfalls of clinical application of sugammadex.

Authors:  Hyung Young Lee; Ki Tae Jung
Journal:  Anesth Pain Med (Seoul)       Date:  2020-07-31

10.  [Perioperative challenges and neuromuscular blockade concerns in robotic thymectomy for myasthenia gravis].

Authors:  Atish Pal; Vikas Gogia; Chetan Mehra
Journal:  Braz J Anesthesiol       Date:  2020-09-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.